Oral Iron Versus Oral Iron Plus a Web-based Behavioral Intervention in Young Children (IRONCHILD)

Model scores of the 29,894 trials active now.

Model score 19% for any early termination, 14% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 8% of the time (159 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2022-03-09. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: therapybrainor equalequal todl
  Phrases that lowered it: childrenmedicinebloodphysical examinationhistory
• Sponsor's past termination rate: 17.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 3 (lowers risk) · Design
• Drug's FAERS reports marked serious: 65.2% (lowers risk) · Drug's FDA history
• Drug's FAERS reports with a death: 8.1% (lowers risk) · Drug's FDA history
• Design: parallel (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 43 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 317 (lowers risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports before start: 142146 (lowers risk) · Drug's FDA history
• Minimum age: 1 (lowers risk) · Who can join
• Primary purpose: treatment (raises risk) · Design
• Maximum age: 4 (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Responsible party: principal investigator (lowers risk) · Design
• Drugs with FDA adverse-event history: 3 (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Effectiveness of Oral Iron Therapy in Iron Deficiency Anemia With Daily vs Alternate Day Dosing NCT07267975 · started 2025 · scored riskier than 20% of active trials completed
• Daily vs. Every Other Day Oral Iron Supplementation in Patients With Absolute Iron Deficiency Anemia NCT03725384 · started 2019 · scored riskier than 39% of active trials completed
• Enhancing Treatment of Iron Deficiency and Iron Deficiency Anemia With an Antioxidant, Vitamin E NCT01700426 · started 2011 · scored riskier than 12% of active trials completed
• Thrice-weekly Versus Thrice-daily Oral Ferrous Fumarate Treatment in Adult Patients With Iron Deficiency Anemia NCT04130828 · started 2020 · scored riskier than 50% of active trials completed
• Iron Dextran Versus Oral Iron for Treating Iron Deficiency Anemia in Pregnant Women NCT03212781 · started 2016 · scored riskier than 12% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.